Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

NantKwest Inc. (NK)

4.93   0.04 (0.82%) 02-26 16:00
Open: 4.7 Pre. Close: 4.89
High: 5.1 Low: 4.691
Volume: 750,075 Market Cap: 485M
NantKwest Inc is a biotechnology firm operating mainly in the United States. It undertakes research and discovery of drugs to cure virally-induced cancers, bacterial and fungal diseases. Its pipeline product includes taNK, haNK, and aNK.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.112 - 5.146 5.146 - 5.176
Low: 4.611 - 4.652 4.652 - 4.689
Close: 4.865 - 4.931 4.931 - 4.991

Technical analysis

as of: 2020-02-26 4:30:55 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 7.63     One year: 8.96
Support: Support1: 4.69    Support2: 3.90
Resistance: Resistance1: 6.53    Resistance2: 7.67
Pivot: 6.04
Moving Average: MA(5): 5.39     MA(20): 6.19
MA(100): 3.28     MA(250): 2.04
MACD: MACD(12,26): -0.05     Signal(9): 0.23
Stochastic oscillator: %K(14,3): 9.92     %D(3): 12.69
RSI: RSI(14): 39.01
52-week: High: 9.90  Low: 0.95  Change(%): 336.3
Average Vol(K): 3-Month: 225863  10-Days: 99448

Price, moving averages and Bollinger Bands

Price and moving averages has closed below its Short term moving average. Short term moving average is currently above mid-term; AND above long term moving averages. From the relationship between price and moving averages; we can see that: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
NK has closed above bottom band by 0.1%. Bollinger Bands are 42.9% wider than normal. The large width of the bands suggest high volatility as compared to NK's normal range. The bands have been in this wide range for 0 bars. This is a sign that the current trend might continue.

Headline News

The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs on Jan. 16.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aimmune Therapeutics Inc (NASDAQ: AIMT ) Arvinas Inc (NASDAQ: ARVN ) AtriCure Inc. (NASDAQ: ATRC ) AVITA MED LTD/S ADR (NASDAQ: RCEL ) ChemoCentryx Inc (NASDAQ: CCXI ) Collegium Pharmaceutical Inc (NASDAQ: COLL ) DENTSPLY SIRONA Inc (NASDAQ: XRAY ) Eli Lilly And Co (NYSE: LLY ) Epizyme Inc (NASDAQ: EPZM ) Fate Therapeutics Inc (NASDAQ: FATE ) Foamix Pharmaceuticals Ltd (NASDAQ: FOMX ) Fortress Biotech (NASDAQ: FBIO ) (announced award of pediatric disease designation for its partner company Cyprium's CUTX-101, which is being evaluated for Menkes disease) Frequency Therapeutics Inc (NASDAQ: FREQ ) GALAPAGOS NV/S ADR (NASDAQ: GLPG ) Global Blood Therapeutics Inc (NASDAQ: GBT ) Halozyme Therapeutics, Inc. (NASDAQ: HALO ) Hologic, Inc. (NASDAQ: HOLX ) HEALTH SCIENCES/SH (NASDAQ: IMVT ) Inspire Medical Systems Inc (NYSE: INSP ) Insulet Corporation (NASDAQ: PODD ) Johnson & Johnson (NYSE: JNJ Medtronic PLC (NYSE: MDT ) Masimo Corporation (NASDAQ: MASI ) Medpace Holdings Inc (NASDAQ: MEDP ) Mersana Therapeutics Inc (NASDAQ: MRSN ) Mesoblast limited (NASDAQ: MESO ) Minerva Neurosciences Inc (NASDAQ: NERV ) Nantkwest Inc (NASDAQ: NK ) …

Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference
CULVER CITY, Calif.--(BUSINESS WIRE)--Patrick Soon-Shiong, M.D., Chairman and CEO of NantKwest, Inc. and ImmunityBio, Inc. presented an update of the Cancer Breakthrough 2020 Initiative (the “Initiative”) and findings on the preliminary safety and early signals of efficacy in Phase 1 and 2 trials for multiple tumor types at the 2020 J.P. Morgan Healthcare Conference on January 14, 2020 in San Francisco. “We hypothesized that a common treatment protocol that harnesses both the natural-killer cel

Financial Analysis

Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Click here to get more fundamental analysis.
Tweet this page Share on Facebook
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  Nasdaq Global Select
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. (M) 98.37
Shares Float (M) 34.03
% Held by Insiders 71.81
% Held by Institutions 6.19
Shares Short (K) 2830
Shares Short P. Month (K)

Stock Financials

EPS -0.750
Book Value (p.s.) 1.380
PEG Ratio 4.93
Profit Margin
Operating Margin -167185.36
Return on Assets (ttm) -23.7
Return on Equity (ttm) -45.3
Qtrly Rev. Growth -61.3
Gross Profit (p.s.)
Sales Per Share
EBITDA (p.s.) -0.599
Qtrly Earnings Growth
Operating Cash Flow (M) -60.51
Levered Free Cash Flow (M) -42.76

Stock Valuations

P/E -6.57
P/E Growth Ratio 0.01
P/BV 3.57
P/CF -8.01

Dividends & Splits

Dividend Yield
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Forward Dividend
Last Split Date 2012-08-16
Last Split Ratio 8
7 Binary Options
Your Ad Here
Stock Chart
Stoxline Lite
Stoxline Pro
Option Calculator
(c) 2006-2019 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.